tiprankstipranks
Ultragenyx Pharmaceutical, Inc. (RARE)
NASDAQ:RARE
US Market
RARE
Ultragenyx Pharmaceutical
RESEARCH TOOLSreports
Want to see RARE full AI Analyst Report?

Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

1,229 Followers
See the Price Targets and Ratings of:

RARE Analyst Ratings

Strong Buy
15Ratings
Strong Buy
13 Buy
2 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Ultragenyx
Pharmaceutical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RARE Stock 12 Month Forecast

Average Price Target

$50.93
▲(89.33% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $50.93 with a high forecast of $96.00 and a low forecast of $27.00. The average price target represents a 89.33% change from the last price of $26.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","97":"$97","39.25":"$39.3","58.5":"$58.5","77.75":"$77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$96.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.92857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.93</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,39.25,58.5,77.75,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,30.37846153846154,35.846923076923076,41.315384615384616,46.783846153846156,52.252307692307696,57.720769230769235,63.189230769230775,68.65769230769232,74.12615384615385,79.5946153846154,85.06307692307693,90.53153846153846,{"y":96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,26.911428571428573,28.912857142857142,30.914285714285715,32.91571428571429,34.91714285714286,36.91857142857143,38.92,40.92142857142858,42.92285714285715,44.924285714285716,46.92571428571429,48.92714285714286,{"y":50.92857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.91,25.07076923076923,25.231538461538463,25.392307692307693,25.553076923076922,25.713846153846156,25.874615384615385,26.035384615384615,26.196153846153845,26.356923076923078,26.517692307692307,26.678461538461537,26.83923076923077,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.99,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.77,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.38,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.91,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$96.00Average Price Target$50.93Lowest Price Target$27.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on RARE
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
22.68%
Upside
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on RARE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$50
Buy
85.87%
Upside
Reiterated
08/10/26
Ultragenyx: Buy Rating Reiterated as Strong 2Q26 Beat, Pipeline Milestones Support Unchanged $50 Price Target
Wedbush Analyst forecast on RARE
Laura Chico
Wedbush
Wedbush
$30
Hold
11.52%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Canaccord Genuity Analyst forecast on RARE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$79→$81
Buy
201.12%
Upside
Reiterated
08/05/26
Ultragenyx price target raised to $81 from $79 at CanaccordUltragenyx price target raised to $81 from $79 at Canaccord
Citi Analyst forecast on RARE
Yigal Nochomovitz
Citi
Citi
$45
Buy
67.29%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Bank of America Securities Analyst forecast on RARE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (NYSE: STVN), Ultragenyx Pharmaceutical (NASDAQ: RARE) and PROCEPT BioRobotics (NASDAQ: PRCT)
Barclays Analyst forecast on RARE
Eliana Merle
Barclays
Barclays
$43
Buy
59.85%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on RARE
Benjamin Burnett
Wells Fargo
Wells Fargo
$47→$45
Buy
67.29%
Upside
Assigned
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
RBC Capital Analyst forecast on RARE
Luca Issi
RBC Capital
RBC Capital
$40
Buy
48.70%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on RARE
Yaron Werber
TD Cowen
TD Cowen
$49
Buy
82.16%
Upside
Assigned
08/04/26
Ultragenyx: Strong Q2 Beat, Clear Path to FY27 Profitability and Catalyst-Rich 2H26 Support Buy Rating
Morgan Stanley Analyst forecast on RARE
Maxwell Skor
Morgan Stanley
Morgan Stanley
$67
Buy
149.07%
Upside
Reiterated
08/04/26
Ultragenyx: Strong Commercial Momentum and Diversified Late-Stage Pipeline Support Buy Rating and Unchanged $67 Price Target
Cantor Fitzgerald Analyst forecast on RARE
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$96
Buy
256.88%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Guggenheim Analyst forecast on RARE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$43→$35
Buy
30.11%
Upside
Reiterated
08/03/26
Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)
Goldman Sachs Analyst forecast on RARE
Salveen Richter
Goldman Sachs
Goldman Sachs
$25→$27
Hold
0.37%
Upside
Reiterated
07/20/26
Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on RARE
Anupam Rama
J.P. Morgan
J.P. Morgan
$72
Buy
167.66%
Upside
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Evercore ISI Analyst forecast on RARE
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$33
Buy
22.68%
Upside
Reiterated
08/10/26
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI
H.C. Wainwright Analyst forecast on RARE
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$50
Buy
85.87%
Upside
Reiterated
08/10/26
Ultragenyx: Buy Rating Reiterated as Strong 2Q26 Beat, Pipeline Milestones Support Unchanged $50 Price Target
Wedbush Analyst forecast on RARE
Laura Chico
Wedbush
Wedbush
$30
Hold
11.52%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Canaccord Genuity Analyst forecast on RARE
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$79→$81
Buy
201.12%
Upside
Reiterated
08/05/26
Ultragenyx price target raised to $81 from $79 at CanaccordUltragenyx price target raised to $81 from $79 at Canaccord
Citi Analyst forecast on RARE
Yigal Nochomovitz
Citi
Citi
$45
Buy
67.29%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Allogene Therapeutics (NASDAQ: ALLO)
Bank of America Securities Analyst forecast on RARE
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Stevanato Group (NYSE: STVN), Ultragenyx Pharmaceutical (NASDAQ: RARE) and PROCEPT BioRobotics (NASDAQ: PRCT)
Barclays Analyst forecast on RARE
Eliana Merle
Barclays
Barclays
$43
Buy
59.85%
Upside
Reiterated
08/05/26
Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)
Wells Fargo Analyst forecast on RARE
Benjamin Burnett
Wells Fargo
Wells Fargo
$47→$45
Buy
67.29%
Upside
Assigned
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Spyre Therapeutics (NASDAQ: SYRE), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Bruker (NASDAQ: BRKR)
RBC Capital Analyst forecast on RARE
Luca Issi
RBC Capital
RBC Capital
$40
Buy
48.70%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Ultragenyx Pharmaceutical (RARE)
TD Cowen Analyst forecast on RARE
Yaron Werber
TD Cowen
TD Cowen
$49
Buy
82.16%
Upside
Assigned
08/04/26
Ultragenyx: Strong Q2 Beat, Clear Path to FY27 Profitability and Catalyst-Rich 2H26 Support Buy Rating
Morgan Stanley Analyst forecast on RARE
Maxwell Skor
Morgan Stanley
Morgan Stanley
$67
Buy
149.07%
Upside
Reiterated
08/04/26
Ultragenyx: Strong Commercial Momentum and Diversified Late-Stage Pipeline Support Buy Rating and Unchanged $67 Price Target
Cantor Fitzgerald Analyst forecast on RARE
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$96
Buy
256.88%
Upside
Reiterated
08/04/26
Cantor Fitzgerald Remains a Buy on Ultragenyx Pharmaceutical (RARE)
Guggenheim Analyst forecast on RARE
Debjit Chattopadhyay
Guggenheim
Guggenheim
$43→$35
Buy
30.11%
Upside
Reiterated
08/03/26
Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)
Goldman Sachs Analyst forecast on RARE
Salveen Richter
Goldman Sachs
Goldman Sachs
$25→$27
Hold
0.37%
Upside
Reiterated
07/20/26
Goldman Sachs Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)
J.P. Morgan Analyst forecast on RARE
Anupam Rama
J.P. Morgan
J.P. Morgan
$72
Buy
167.66%
Upside
Reiterated
07/07/26
Ultragenyx: Favorable Risk-Reward Ahead of GTX-102 ASPIRE Readout, Analyst Reiterates Buy and $72 Price Target
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ultragenyx Pharmaceutical

3 Months
Whitney IjemCanaccord Genuity
Success Rate
11/17 ratings generated profit
65%
Average Return
+6.91%
Copying Whitney Ijem's trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +6.91% per trade.
1 Year
Whitney IjemCanaccord Genuity
Success Rate
9/17 ratings generated profit
53%
Average Return
-1.84%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of -1.84% per trade.
2 Years
Yaron WerberTD Cowen
Success Rate
12/32 ratings generated profit
38%
Average Return
-3.96%
Copying Yaron Werber's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -3.96% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RARE Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
20
18
16
14
12
Buy
6
3
3
4
5
Hold
2
2
1
4
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
28
23
20
22
21
In the current month, RARE has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. RARE average Analyst price target in the past 3 months is 50.93.
Each month's total comprises the sum of three months' worth of ratings.

RARE Financial Forecast

RARE Earnings Forecast

Next quarter’s earnings estimate for RARE is -$0.93 with a range of -$1.29 to $0.75. The previous quarter’s EPS was -$0.90. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.
Next quarter’s earnings estimate for RARE is -$0.93 with a range of -$1.29 to $0.75. The previous quarter’s EPS was -$0.90. RARE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Sales Forecast

Next quarter’s sales forecast for RARE is $183.95M with a range of $169.50M to $194.18M. The previous quarter’s sales results were $214.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.
Next quarter’s sales forecast for RARE is $183.95M with a range of $169.50M to $194.18M. The previous quarter’s sales results were $214.00M. RARE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RARE has Performed in-line its overall industry.

RARE Stock Forecast FAQ

What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical, Inc.’s 12-month average price target is 50.93.
    What is RARE’s upside potential, based on the analysts’ average price target?
    Ultragenyx Pharmaceutical, Inc. has 89.33% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RARE a Buy, Sell or Hold?
          Ultragenyx Pharmaceutical, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Ultragenyx Pharmaceutical, Inc.’s price target?
            The average price target for Ultragenyx Pharmaceutical, Inc. is 50.93. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $96.00 ,the lowest forecast is $27.00. The average price target represents 89.33% Increase from the current price of $26.9.
              What do analysts say about Ultragenyx Pharmaceutical, Inc.?
              Ultragenyx Pharmaceutical, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of RARE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.